ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Unravelling the Stage-Shift of Acute Rejection by Urine QSant

W. Yazar1, N. Titzler1, R. Sarwal1, M. Sarwal2, S. Ghosh1

1Nephrosant, Brisbane, CA, 2NephroSant, Brisbane, CA

Meeting: 2022 American Transplant Congress

Abstract number: 1062

Keywords: Biopsy, Kidney, Kidney transplantation, Rejection

Topic: Clinical Science » Kidney » 44 - Kidney Acute Antibody Mediated Rejection

Session Information

Session Name: Kidney Acute Antibody Mediated Rejection

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Suboptimal performance in current methods for allograft monitoring underscores the unmet need for enhanced immunosurveillance accuracy, to uncover the alloimmunity flux. QSant[Yang et al, STM 2020] – a multi-analyte urinary diagnostic assay was developed to profile overall renal transplant health and prognosticate the risk of acute rejection(AR). QScore – A ML-based scaled(0-100) score across measurements of DNA, protein and metabolic biomarkers, enables this prognostication.

*Methods: We analyzed a real-world-data cohort, comprising of 235 urine samples collected from renal transplant patients – between 4/1 and 10/1, 2021 – across 11 US transplant centers. Fresh samples, self-collected by patients in urine-cups with proprietary preservatives were shipped to our CLIA lab and assayed by QSant and QScores reported. Increasing QScore reflects progression in allograft damage post transplantation(figure). A 3-state model is hypothesized informed by the fact that evolution and resolution of rejection is a patchy process and the gold standard biopsy could miss histological signs of rejection depending on the site of the tissue sample. QScore <32 classifies allograft stability/immunoquiescence; QScore between 32-55 exposes a state of alloimmunity flux; and QScore >55 identifies AR presenting high concordance with biopsy-backed histological instability.

*Results: The patients span the entire QScore spectrum. 37.9% of the samples enrich for immunequiescence (QScore<32); 49.8% enrich for the alloimmune flux domain with QScore 32-55 and 12.3% enrich the higher-grade AR domain with a QScore ≥55. Serial QSant monitoring, across a subset of 32 patients, over a period of two consecutive quarters, captures the essence of the alloimmunity flux (p-value: 0.086,Wilcoxon test). 53% [17/32] of the patients encompass the alloimmune injury domain and follow three primary trajectories: i) a planar gradient in QScore across time, showing persistence of alloimmunity(53% [9/17]); ii) a decreasing gradient, delineating patients moving into the immunoquiescent domain, putatively in response to immunomodulation following assessment of active rejection (41%); iii) an increasing gradient, delineating patients moving into the mature AR domain (6%).

*Conclusions: The observed alloimmunity flux suggests precision monitoring with QSant has the potential to differentiate higher-grade AR episodes from evolving/resolving rejection and/or potentially identify ones missed by biopsies. It also presents a paradigm which can potentially stage-shift the detection of rejection, resulting in improved graft and patient survival.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Yazar W, Titzler N, Sarwal R, Sarwal M, Ghosh S. Unravelling the Stage-Shift of Acute Rejection by Urine QSant [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/unravelling-the-stage-shift-of-acute-rejection-by-urine-qsant/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences